Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions
In conclusion, pegylated anti-E6 lipoplexes have demonstrated their efficiency to cross the cellular membrane and to release siRNA into the cytoplasm confirmed by final p53 protein production. Graphical abstract
Source: International Journal of Pharmaceutics - February 27, 2015 Category: Drugs & Pharmacology Source Type: research

Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Abstract Although cancer vaccine-based immunotherapy holds great potential for cancer treatment, tumor-induced dendritic cell (DC) dysfunction remains to be the major obstacle for developing effective vaccines. Compared with normal DCs, tumor-associated DCs (TADCs) are less matured with poor responsiveness to Toll-like receptor (TLR) stimulation, which has been related with STAT3 hyperactivity. In the present study, Poly I:C (PIC, a TLR3 agonist), STAT3 siRNA and OVA antigen were co-encapsulated by poly (ethylene glycol)-b-poly (l-lysine)-b-poly (l-leucine) (PEG-PLL-PLLeu) polypeptide micelles to generate PMP/OVA/...
Source: Biomaterials - December 6, 2014 Category: Materials Science Authors: Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y Tags: Biomaterials Source Type: research

Abstract 5033: Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell
Conclusions: The findings obtained from the current study suggested that 5-FU and DTX may enhance the T cell-stimulating ability of DCs via down-regulation of PD-L1 and PD-L2 mediated by STAT3 inhibition, and that the combination therapy of DC-based cancer vaccine with these anti-cancer drugs may elicit better anti-tumor immune response than only vaccination. Citation Format: Masato Okamoto, Tomoyuki Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki Hamakawa. Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell. [abst...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, M., Tano, T., Goda, H., Fujita, Y., Nakashiro, K.-i., Hamakawa, H. Tags: Immunology Source Type: research

PIAS1 and STAT‐3 impair the tumoricidal potential of IFN‐γ‐stimulated mouse dendritic cells generated with IL‐15
This article is protected by copyright. All rights reserved
Source: European Journal of Immunology - April 28, 2014 Category: Allergy & Immunology Authors: Neale T. Hanke, Collin J. LaCasse, Claire B. Larmonier, Darya Alizadeh, Malika Trad, Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier Tags: Regular Article Source Type: research

PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.
This article is protected by copyright. All rights reserved. PMID: 24777831 [PubMed - as supplied by publisher]
Source: European Journal of Immunology - April 28, 2014 Category: Allergy & Immunology Authors: Hanke NT, Lacasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N Tags: Eur J Immunol Source Type: research

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Abstract Success of an immunotherapy for cancer often depends on the critical balance of T helper 1 (Th1) and T helper 2 (Th2) responses driven by antigen presenting cells, specifically dendritic cells (DCs). Th1-driven cytotoxic T cell (CTL) responses are key to eliminating tumor cells. It is well established that CpG oligonucleotides (ODN), a widely studied Toll-like receptor 9 (TLR9) agonist, used to enhance Th1 response, also induces high levels of the anti-inflammatory, Th2-promoting cytokine IL10, which could dampen the resulting Th1 response. Biomaterials-based immunomodulatory strategies that can reduce IL...
Source: Biomaterials - April 7, 2014 Category: Materials Science Authors: Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K Tags: Biomaterials Source Type: research

Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Recent studies have underscored the importance of memory T cells in mediating protective immunity against pathogens and cancer. Pharmacological inhibition of regulators that mediate T cell differentiation promotes the differentiation of activated CD8+ T cells into memory cells. Nonetheless, pharmacological agents have broad targets and can induce undesirable immunosuppressive effects. Here, we tested the hypothesis that aptamer-targeted siRNA inhibition of mTOR complex 1 (mTORC1) function in CD8+ T cells can enhance their differentiation into memory T cells and potentiate antitumor immunity more effectively than the pharma...
Source: Journal of Clinical Investigation - December 4, 2013 Category: Biomedical Science Authors: Alexey Berezhnoy, Iris Castro, Agata Levay, Thomas R. Malek, Eli Gilboa Source Type: research

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
Conclusion. These results suggest that the efficacy of melanoma DC–based immunotherapy is enhanced when tumor antigen–loaded DCs used for vaccination express cPs. Trial registration. Clinicaltrials.gov NCT00672542. Funding. Duke Clinical Research Institute/Duke Translational Medicine Institute, Duke Melanoma Consortium, and Duke University Department of Surgery.
Source: Journal of Clinical Investigation - July 1, 2013 Category: Biomedical Science Authors: Jens Dannull, N. Rebecca Haley, Gary Archer, Smita Nair, David Boczkowski, Mark Harper, Nicole De Rosa, Nancy Pickett, Paul J. Mosca, James Burchette, Maria A. Selim, Duane A. Mitchell, John Sampson, Douglas S. Tyler, Scott K. Pruitt Source Type: research

Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine.
Abstract A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers. Here, we report an unexpected function of GV1001 as a cell-penetrating peptide (CPP). GV1001 was delivered into a variety of cells including various cancer cell lines and primary blood cells. Moreover, the delivered GV1001 was predominantly located in the cytoplasm of the cells, while a significantly higher proportion of TAT peptide was localized in the nucleus. Macromolecules such as proteins, DNA and siRNA, which were linked to GV1001 by direct covalent conjugation or n...
Source: Biomaterials - July 1, 2013 Category: Materials Science Authors: Lee SA, Kim BR, Kim BK, Kim DW, Shon WJ, Lee NR, Inn KS, Kim BJ Tags: Biomaterials Source Type: research

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research

A Novel and Efficient Technology for Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remains significant issue. Without a solution to this delivery problem, RNAi cannot fulfill its therapeutic promise. Investigators at the National Institutes of Health have developed novel compositions...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: admin Source Type: research